Edward M. MD Kaye - Oct 8, 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Oct 8, 2025
Transactions value $
-$735,000
Form type
4
Date filed
10/10/2025, 04:12 PM
Previous filing
Oct 6, 2025
Next filing
Oct 16, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kaye Edward M. MD Director C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 2025-10-10 0001522780

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $15K +25K +50.89% $0.60 74.1K Oct 8, 2025 Direct F1
transaction STOK Common Stock Sale -$750K -25K -33.73% $30.00 49.1K Oct 8, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Stock Option (Right to Buy) Options Exercise $0 -25K -4.4% $0.00 543K Oct 8, 2025 Common Stock 25K $0.60 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
F2 The option vested as to 1/4th of the total award on October 17, 2018, with another 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Accordingly, this stock option is now fully vested.